Retatrutide (an investigational “triple agonist” obesity drug) has shown very large weight-loss results in recent reports, alongside a notable rate of side effects and treatment discontinuations.[1][5]
Latest reported weight-loss results (highlights)
- New late-stage trial reporting (Eli Lilly): One report says patients lost an average of about 70.3 lb over 80 weeks, with 45% of people on the 12 mg dose losing up to 30% of body weight.[5]
- Another summary of a Phase 3 study (TRIUMPH-4 context in coverage): In a 68-week Phase 3 study, one report states that those on the highest dose who stayed on treatment lost 28.7%, while a different analysis including people who stopped early showed 23.7%.[1]
- Background on mechanism (why it’s “triple”): Coverage describes retatrutide as targeting GIP, GLP-1, and glucagon receptors.[5]
What’s being said about tolerability
- Reported coverage emphasizes that side effects were high and that many participants discontinued treatment—some because they felt they were losing too much weight.[1]
How to interpret this as “latest news”
These are news summaries of trial results released by the company or reported by major outlets, rather than a complete FDA-approved label yet.[5][1]
If you tell me whether you want (a) Phase 3 details, (b) side-effect rates, or (c) how it compares to semaglutide/tirzepatide, I can focus the summary accordingly.
Sources
Eli Lilly's next-gen obesity drug delivered major weight loss in a trial, but some patients stopped using it after losing too much weight.
www.statnews.comA new weight loss injection called retatrutide has shown remarkable results in…
www.diabetes.co.uk"Retatrutide delivered powerful weight loss," Leerink Partners analyst David Risinger told investors on Thursday morning. The study's results are the latest signal that retatrutide may be the most effective weight-loss medication in development. As such, retatrutide is a highly anticipated addition to Lilly's (LLY) obesity portfolio, which already includes Zepbound, a weekly GLP-1/GIP shot, and Foundayo, a daily non-peptide GLP-1 pill. It is sometimes referred to as "triple G" because it...
www.morningstar.comParticipants of a phase III trial of investigational weight-loss drug retatrutide showed an average weight loss of almost 30% and “substantial” relief from knee osteoarthritis, manufacturer Eli Lilly and Company has announced. In a statement published on 11 December 2025, Eli Lilly reported results from its TRIUMPH-4 trial, which involved 445 participants aged over 18 […]
pharmaceutical-journal.comThe company’s triple-acting drug retatrutide helped Phase 2 study participants lose a quarter of their body weight, more than what’s been observed in testing of other medicines.
www.biopharmadive.comPeople treated with injections of retatrutide—an agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors—lost substantially more weight than those who received a placebo, according to results from a phase 2 trial involving 338 adults with obesity or...
jamanetwork.com(UPDATED) The once-weekly injectable targeting three hormone receptors hints at “fundamental change” for cardiometabolic disease.
www.tctmd.comFindings demonstrated that participants with obesity lost more than 24% of their starting body weight within 48 weeks of treatment with the highest dose of retatrutide. Additionally, 100% of the participants taking either of the two higher doses (8 mg and 12 mg) lost at least 5% or more of their body weight. The results indicate that retatrutide has an overall safety and tolerability profile similar to other nutrient-stimulated hormone-based therapies, such as GLP-1 receptor agonists approved...
diabetes.orgThe results of the drug are comparable to what is seen with bariatric surgery, according to Eli Lilly.
abcnews.com